Introduction
Imaging plays a pivotal role in the management of human brain tumors. Anatomical features are routinely assessed through magnetic resonance imaging (MRI) and computed tomography (CT). Advanced MRI techniques and positron emission tomography (PET) imaging offer physiologic, metabolic and/or functional information about brain tumor biology beyond standard MRI and CT evaluations.
With combined PET-MRI scanners, relationships among different aspects of brain tumor metabolism can be simultaneously explored. The purpose of this review is to provide a practical overview of current multi-modality imaging of brain tumors.
Anatomic MRI and CT
Neuroimaging of brain tumors is performed using MRI with gadolinium contrast, except in cases where contraindications exist (1) (2) (3) (4) . Anatomical MRI assessments form the basis upon which clinical management decisions are made. Although MRI is generally superior to CT for imaging brain tumors, CT remains more readily available and provides important complementary information. CT remains the gold standard for depiction of acute hemorrhage, calcifications, and osseous features.
For example, calcifications may be observed in oligodendrogliomas, whereas hyperdensity suggests a cellular tumor such as lymphoma. Despite these situational advantages, some limitations of CT compared to MRI include inferior soft tissue characterization, posterior fossa beam hardening artifact and the use of ionizing radiation.
In clinical practice, 1H-MRS is operator-dependent because a volume of interest must be selected and carefully shimmed to avoid areas of macroscopic necrosis, hemorrhage, calcification and/or cysts. Either single-voxel or multi-voxel techniques may be used, or both may be obtained sequentially. Echo time must also be selected, necessitating a decision to obtain minor metabolite peaks using short echo times (e.g. on the order of 30 ms), to display the characteristic inversion of lactate below the MR spectrum baseline (using long echo times such as 135 or 144 ms), or to obtain a cleaner spectrum comprised of the major metabolites choline, creatine, N-acetylaspartate and lactate (using longer echo times such as 270 or 288 ms). The absolute quantification metabolites using MR spectroscopy remains challenging in the clinical environment, therefore semi-quantitative assessments of MR spectra using metabolite peak ratios are often used clinically.
Perfusion MRI
MR perfusion characterizes vascularity within brain tumors and surrounding tissue. Many brain tumors exhibit an increased density of vessels per unit volume of tissue, most often quantified by MR perfusion as an increase in cerebral blood volume (CBV) or cerebral blood flow (CBF) within the tumor as compared to normal brain tissue (9). Neovessels within brain tumors also frequently lack blood-brain barrier integrity, leading to an increase in vascular permeability (10). A variety of different MR imaging strategies can be used to obtain MR perfusion information, each with its own strengths and weaknesses (11).
Dynamic contrast-enhanced (DCE) perfusion is obtained via serial T1-wieghted MR imaging during intravenous gadolinium contrast injection, and most often quantifies the vascular leakage constant, Ktrans (12). Dynamic susceptibility-contrast (DSC) T2-and/or T2*-weighted perfusion is similarly obtained during first-pass intravenous bolus of gadolinium contrast, resulting in a drop in MR signal that can characterize vessel density (macro-vessel and/or micro-vessel, depending on the precise sequence employed) in the form of relative CBV measured within a region of interest.
DSC perfusion is more rapidly acquired and more widely used than DCE in clinical practice. DSC may also detect increased microvessel density within non-enhancing or equivocally enhancing tumors with a relatively intact blood-brain barrier (13), although T1-leakage complicates DSC quantification in enhancing tumors (14).
Ferumoxytol, a super-paramagnetic iron oxide nanoparticle, acts as a blood pool agent shortly after administration, thus avoiding the need for leakage correction and improving the accuracy of CBV quantification (15). However, DCE images are typically higher resolution than DSC images with fewer magnetic susceptibility artifacts, and while MR signal intensity does not scale linearly with gadolinium contrast concentration, this scaling problem is worse for DSC than DCE (10, 16). Although MR perfusion methods are relatively operator-independent, the selection of which technique to use, how to account for contrast leakage effects, how to define a region of interest, and how to quantify the resulting parametric information is not. 
Functional MRI
Functional MRI (fMRI) is based on the principle that areas of neuronal activation utilize oxygenated blood to a greater degree than areas at rest. Blood oxygen level dependent (BOLD) MRI is a rapid T2*-weighted sequence that provides a means of serially imaging the brain and its utilization of oxygen in response to simple motor or language testing (32). 
Treatment Response Assessment
Updated criteria for therapeutic response proposed by the response assessment in neuro-oncology (RANO) working group continue to gain acceptance over previous Macdonald criteria (1-3). Similar to response criteria applied elsewhere in the body, complete disappearance or decrease in size of all measurable contrast-enhancing lesions as compared to pre-treatment baseline is taken as evidence of treatment response, whereas an increase in size indicates treatment failure. RANO criteria were prompted by the recognition of certain MRI pitfalls-namely pseudoprogression and pseudo-response-that are commonly observed in the posttreatment setting (1, 38, 39) . Pseudo-progression refers to transient increase in size of enhancement or the appearance of new enhancement in the early-delayed (first 3-6 months) post-radiation period, a phenomenon more commonly recognized in the era of combined chemoradiation therapy for initial treatment of glioblastoma (38). Gadolinium-enhanced MRI cannot distinguish true early progression from pseudoprogression (40). Pseudo-response refers to decreased tumoral enhancement resulting from anti-angiogenic therapy. In recognition of these confounding factors, the RANO working group proposed updated criteria for response assessment in high-grade gliomas [ Figure 1 ].
Given that response assessment with MRI begins at ten weeks following the initiation of radiotherapy, strategies for earlier identification of non-responding patients have been proposed. Parametric response mapping (PRM) incorporates both ADC and relative CBV maps acquired prior to treatment and at 3 weeks during treatment into a voxel-by-voxel image analysis method. Using ADC and relative CBV individually, PRM has been reported to predict outcome following radiotherapy in high-grade glioma (41, 42) . A large fraction of the tumor with significantly increasing ADC values at 3 weeks correlated with improved overall survival, whereas a small fraction of the tumor with decreasing relative CBV also correlated with an improved outcome. PRM using combined ADC and CBV has a stronger correlation to survival than baseline clinical or treatment response imaging metrics alone (43).
Although there is inconclusive evidence that late-delayed (>9-12 months) postradiation effects can be reliably distinguished from tumor recurrence, multi-voxel 1H-MRS has been suggested to distinguish between glioma recurrence and radiation injury, as have DCE perfusion, DSC perfusion, and diffusion/DTI. Some investigations have explored multi-parametric approaches to this problem with varied results (44-46).
Post-Surgical Assessment
Post-operative imaging for residual tumor presents a distinct set of challenges (4).
Specifically, a neurosurgeon's operative report should not be used to determine the extent of tumor resection. Instead, gadolinium-enhanced MRI should be performed following tumor resection with 24-48 hours; beyond that timeframe, post-operative resection margins may show enhancement that could be misinterpreted as residual tumor. In this setting, DWI is particularly useful for identifying areas of postsurgical injury along or near the resection margin; specifically, these diffusionrestricted areas may show enhancement on subsequent MRI scans that could be misinterpreted as early tumor recurrence (47). 
18F-FDG PET

18F-FLT PET
Thymidine is the nucleic acid specific to DNA. Thymidine is a substrate for thymidine kinase 1, which varies during the cell cycle, and for mitochondrial thymidine kinase 2, which limits specificity for active cell division. The thymidine analog 3-deoxy-3-18F-fluorothymidine (18F-FLT) becomes trapped by thymidine kinase 1, analogous to the manner in which 18F-FDG is trapped by hexokinase (56).
Unlike thymidine, 18F-FLT is a poor substrate for mitochondrial thymidine kinase 2, and thus its uptake is specific to the cell cycle (57). Therefore, 18F-FLT PET can provide a quantitative measure of mitotic activity and cell division.
However, the blood brain barrier limits cellular uptake of 18F-FLT (58). 18F-FLT uptake is a function of the plasma input function and the rate of its transport across the blood-brain barrier; therefore, a complete kinetic model of 18F-FLT uptake, transport and metabolism is needed to accurately quantify DNA synthesis in brain tumors (59). Without such a model, 18F-FLT is unlikely to perform better than an inert contrast agent, such as gadolinium chelates, in brain tumor imaging [ Figure 3 ].
18F-FLT PET identifies recurrent high-grade glioma and correlates with survival
better than 18F-FDG (60) , and quantitative 18F-FLT PET with kinetic modeling may distinguish tumor recurrence from radionecrosis (61) . However, an assumption that 18F-FLT SUV reflects primarily uptake of the tracer into the DNA synthesis pathway is potentially misleading in CNS neoplasms (62) .
18F-FMISO PET
Hypoxia is an important factor in malignant tumor progression and resistance to therapy (63) . Conventional photon radiation therapy depends upon available oxygen to form free radicals that damage DNA, and thereby induce apoptosis and inhibit tumor growth. Persistence of tumor cells within a hypoxic microenvironment correlates with poor prognosis. Hypoxia-inducible factors mediate changes that enable tumors to survive under hypoxic conditions (64) .
Some of these changes, including neoangiogenesis resulting from production of vascular endothelial growth factor, pose a significant barrier to treatment (65).
18F-Fluoromisonidazole (18F-FMISO) freely crosses the blood brain barrier and rapidly equilibrates within tissues independent of perfusion (66, 67) . 18F-FMISO is trapped only within viable cells under severely hypoxic conditions. 18F-FMISO PET images are analyzable through a relatively simple calculation using calibrated blood sampling to obtain a tumor-to-blood ratio. A tumor-to-blood ratio above 1.2 identifies 18F-FMISO uptake within hypoxic tissue above background normal tissue, and regions of interest drawn around visible tumor involvement on MRI allow hypoxic volume and tumor-to-blood maximum value to be calculated; these parameters correlate with worsened prognosis in glioblastoma independent of other prognostic factors (68) . In a more recent prospective study of glioma patients 
PET-MRI of Brain Tumors
The first application for integrated PET-MRI in humans was to evaluate feasibility in the brain (74) . Initial PET-MRI research focused on correlations to PET-CT in assessment of primary CNS tumors (75) . The simultaneous acquisition of coregistered PET and MRI data enables direct correlation among different imaging parameters acquired during a single imaging session, thus enabling development of applications that exploit the complementary nature of metabolic and anatomic information from each modality (76) . 
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